drugset

drugset / Trial / NCT00300716

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

NCT00300716 ↗

Phase 2/3 Completed 82 enrolled Oregon Health and Science University Forest Laboratories · collab MS-Hub Seattle · collab University of Southern California · collab University of Texas Southwestern Medical Center · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

Timeline

Start: 2004-04
Primary completion: 2009-01
Completion: 2009-01

Publications

Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, Bourdette D. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010 Jun;16(6):715-23. doi: 10.1177/1352458510367662. Epub 2010 May 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	20 mg	—

Indications